Fig. 2From: Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case reportEvolution of pulmonary function tests from 2006 to January 2018 with corresponding timeline of treatments received for sporadic LAM. Radiologic findings in 2013, in 2015 before initiation of Nivolumab. In 2017 before addition of Sirolimus to Nivolumab and in June 2018 during association with nivolumab and sirolimusBack to article page